The Use of Pathologic Factors to Assist in Establishing Adequacy of Excision Prior to Radiation Therapy in Patients Treated with Breast Conserving Therapy.

Slides:

Advertisements

Similar presentations

Mammary ductal carcinoma

Advertisements

Baptist Health System General Surgery Residency Program

Oncotype DX® Breast Cancer Assay Clinical Data Review

The Present and Future of Genomics in DCIS

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

DCIS – Are we cutting it? Dr Alex Lemaigre With thanks to:

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

AJCC TNM Staging 7th Edition Breast Case #3

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Margins: less is just as good

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Ductal Carcinoma in situ

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Dilemma in management of DCIS

Ductal Carcinoma In Situ (DCIS)

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Tutorial on Breast Pathology Part I: Ductal and Lobular Neoplasias Thomas J Lawton MD, Director Seattle Breast Pathology Consultants, LLC Seattle, WA.

Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.

The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.

Management of DCIS KWH Experience Dr. Carmen Ho.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.

Histopathological evaluation of lymphatic nodules in cancer of the uterine cervix Coordinators: First Author: Asist. Univ. Dr. Chira Liliana Stud. Bogdan.

Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.

Oncology / Dysplasia Unit Royal Women’s Hospital, Carlton, Victoria Do all patients with invasive cervical carcinoma need a radical hysterectomy? Leuven.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Radiological-histological size correlation in triple-negative breast cancer (TNBC) Abstract # 8254 C Thibault 1, M Gosset 2, F Chamming’s 3, M-A Lefrere-Belda.

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

Salvage Nipple-Sparing Mastectomy and Immediate Breast Reconstruction after Previous Breast Conservation Therapy: Same Safety, Better Cosmesis Che-Hsiung.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Paper of The Week Follow-up may not be beneficial after treatment of grade 1 breast cancer M. Kontos, D. Allen, D. T. Trafalis, G. Jones, H. Garmo, L.

W. Scott Campbell, MBA, PhD James R. Campbell, MD

Operative Approach and

Breast conserving surgery (BCT): Every millimetre counts

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

Margin Status in Oral Cancer: Requirement for Reassessment

Does Adenomyosis Impede Spread of Endometrial Cancer

SPECIMEN SONOGRAM - Procedure

Meticulous Pathologic Evaluation to Ensure Negative Margins Facilitates a Low Risk of Local Recurrence of Dermatofibrosarcoma Protuburans (DFSP) Departments.

Dr T P E Wells 13 July 2018 Breast SSG Bath

Neal S Goldstein, MD The Annals of Thoracic Surgery

SCC MDT Service Evaluation

Presentation transcript:

The Use of Pathologic Factors to Assist in Establishing Adequacy of Excision Prior to Radiation Therapy in Patients Treated with Breast Conserving Therapy The Use of Pathologic Factors to Assist in Establishing Adequacy of Excision Prior to Radiation Therapy in Patients Treated with Breast Conserving Therapy Frank A. Vicini, M.D. 1, Neal S. Goldstein M.D. 2, Helen Pass, M.D. 3, Larry L. Kestin, M.D. 1 Departments of Radiation Oncology 1, Pathology 2, and Surgery 3, William Beaumont Hospital, Royal Oak, MI. Helen Pass, M.D. 3, Larry L. Kestin, M.D. 1 Departments of Radiation Oncology 1, Pathology 2, and Surgery 3, William Beaumont Hospital, Royal Oak, MI.

Background: We reviewed our experience in patients with early stage breast carcinoma treated with breast conserving therapy (BCT) to identify pathologic factors useful in defining adequacy of excision prior to radiation therapy (RT). Methods: All slides from 607 consecutively treated cases of stage I/II breast carcinoma were reviewed by one pathologist. Numerous pathologic factors were evaluated for their association with ipsilateral breast failure (IBF). Margin distance was classified as negative (>½ low-power field [LPF] from the margin), near ( ½ low-power field [LPF] from the margin), near (<1/2 LPF from the margin), or positive. The amount of carcinoma near the final margin was measured as the width of invasive carcinoma and number of DCIS ducts near the margin and divided into three groups: near-least, near-intermediate and near-greatest amount. Median follow-up was 8.5 years.

Results: Patients with negative, ‘near-least’, ‘near- intermediate’, and ‘near-greatest’ amount of carcinoma near the margin, and positive final margins had 12-year IBF rates of 9%, 6%, 18%, 24%, and 30%, respectively

Results: On multivariate analysis, only the amount of carcinoma near the margin was independently associated with IBF (p<0.001). To help explain these observations, 441 initial and re- excision specimens were examined. The amount of carcinoma near the initial margin and the invasive carcinoma-to-specimen maximum dimension ratio were significantly associated with greater amounts of residual carcinoma in adjacent breast parenchyma.

Conclusions: The amount of carcinoma near the margin, in addition to margin status appears to be directly related to an increased risk of IBF in patients treated with BCT. Pathologic factors that incorporate the amount of excised breast parenchyma and amount of carcinoma near the margin may be useful to clinicians in deciding whether a patient has been adequately excised for BCT.